Status:
COMPLETED
Creatine as a Treatment Option for Depression in Methamphetamine Using Females
Lead Sponsor:
Perry Renshaw
Conditions:
Depression
Substance Abuse
Eligibility:
FEMALE
13-64 years
Phase:
PHASE4
Brief Summary
Methamphetamine (MA) is a psychostimulant drug with high abuse potential. MA can be smoked, snorted, injected or ingested orally to produce a release of high levels of dopamine into the brain and redu...
Eligibility Criteria
Inclusion
- Female gender, ages 18-64 years inclusive
- Diagnosis of MA dependence or abuse within the past 12 months, with MA preferred drug of abuse, identified by the SCID-I-RV
- Current diagnosis of Major Depressive Disorder identified by the SCID-I-RV
- Current HAM-D17 score of \> 15
Exclusion
- Diagnosis of bipolar disorder, schizophrenia, or schizoaffective disorder, identified by the SCID-I-RV
- History of or current diagnosis of renal disease, such as chronic renal failure, acute renal failure or end stage renal disease
- Diabetes type I or II
- Colitis or diverticulitis
- Seizure disorder
- Current serious suicide risk identified by the Columbia Severity Suicide Rating Severity
- Current treatment with an antipsychotic, mood stabilizer, or antidepressant
- Positive HIV test
- Active Hepatitis C
- Contraindication to magnetic resonance scan
Key Trial Info
Start Date :
January 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2015
Estimated Enrollment :
14 Patients enrolled
Trial Details
Trial ID
NCT01514630
Start Date
January 1 2013
End Date
February 1 2015
Last Update
June 29 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The Brain Institute of the University of Utah
Salt Lake City, Utah, United States, 84108